SRSF2 and acute myeloid leukemia: The present study also shed light on the prevalence of SRSF2 P95H missense mutation in CPT1Alow AML patients which is located in the RNA binding domain of the SRSF2 splicing factor protein and leads to distorted RNA binding of SRFS2 (56).